期刊文献+

脑梗塞、冠心病血脂代谢与纤溶酶原激活物抑制物关系的研究

Relationship between cerebral infarction, coronary heart disease and plasminogen activator inhibitors
下载PDF
导出
摘要 为探讨脑梗塞及冠心病血脂代谢紊乱与血浆纤溶酶原激活物抑制物 1(PAI -1)活性变化的关系及意义 ,采取合理有效的干预性治疗方法改善低纤溶状态。测定 112例脑梗塞、81例冠心病患者及 45例健康体检者血总胆固醇 (TC)、甘油三酯 (TG)、低密度脂蛋白胆固醇 (LDLC)、高密度脂蛋白胆固醇 (HDLC)、非高密度脂蛋白胆固醇 (nHDLC) ,同时测定纤溶酶原激活物抑制物活性 (PAI -1∶A)并进行比较分析。结果显示 :脑梗塞组及冠心病组患者血浆TG、nHDLC含量增高 ;血浆PAI -1∶A明显升高 ,与正常组比较差异均有高度显著性 (P <0 .0 1)。经多因素回归分析 ,脑梗塞组及冠心病组TG、nHDLC水平与血浆PAI -1∶A呈正相关 (P <0 .0 1)。提示脑梗塞及冠心病患者组血清TG ,nHDLC增高作为PAI -1∶A增高的独立因素 ,而PAI -1活性增高致心脑血管血栓性疾病的机率增加。纠正血脂代谢紊乱可改善纤溶活性 。 In order to investigate the relationship and significance between the blood-lipid metabolism of cerebral infarction and coronary heart disease and the plasma plasminogen inhibitor activator 1 (PAI-1) activity, the rational effective intervention methods were taken to improve the hypofibrinolytic state. The content of blood total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDLC), high density lipoprotein cholesterol (HDLC) and non high density lipoprotein cholesterol (nHDLC) in 112 patients with cerebral infarction, 81 with coronary heart diseases and 45 healthy individuals were measured, meanwhile, the plasminogen activator inhitor 1 activity (PAI-1:A) was also measured and compared. Results showed that the content of plasma TG, nHDLC increased in patients with cerebral infarction and coronary heart disease, the plasma PAI-1:A increased significantly, and there were significant differences in comparing to the control group (P<0.01). After being analyzed by using multiple factor regression, the levels of TG and nHDLC in the cerebral infarction group and the coronary heart disease group had positive correlation with PAI-1:A (P<0.01). This study indicated that the increasing of serum TG, nHDLC in patients with cerebral infarction and coronary heart disease could only cause the increaseing of PAI-1:A, but the increasing of PAI-1 activity may induce the probability of cardio-cerebral vascular throbotic dieases. The correction of disturbance of blood-lipid metabolism could improve the fibrinolytic activity and result in reducing the incidence of cardio-cerebral blood vessel diseases.
作者 马付坚
出处 《右江民族医学院学报》 2001年第6期872-873,共2页 Journal of Youjiang Medical University for Nationalities
关键词 脑梗塞 冠状动脉疾病 高甘油三酯血症 纤溶酶原激活物抑制物1 危险因素 cerebral infarction coronary artery disease hypertriglyceridemia plasminogen activator inhibitor 1 risk factors
  • 相关文献

参考文献9

  • 1[1]Frost PH, Havel RJ. Rational for use of non-HDL cholesterol rather than LDL cholesterol as a tool for lipoprotein cholesterol screening and assessment of riska therapy [J]. Am J Cardiol,1998;81(4A):26B~31B.
  • 2[2]Urano T, Ihara H, Suzuki Y,et al.Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity [J]. Semin Thromb Hemost,2000;26(1):39~42.
  • 3[3]Zalewski A, Shi Y, Nardone D, et al. Evidence for reduced fibrinolytic activity in unstable angina at rest.Clinical biochemical and angiographic correlates [J]. Circulation,1991;83:1685.
  • 4[4]Grenett HE, Benza RL, Fless GM, et al. Genotype-specific transcriptional regulation of PAI-1 gene by insulin, hypertriglyceridemic VLDL, and Lp(a) in transfected, cultured human endothelial cells [J]. Arterioscler Thromb Vasc Biol,1998;18(11):1803~1809.
  • 5[5]Eriksson P, Nilsson L, Karpe F, et al. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia [J]. Arterioscler Thromb Vasc Biol,1998;18(1):20~26.
  • 6[6]Dichtl W, Ares MP, Stollenwerk M, et al. In vivo stimulation of vascular plasminogen activator inhibitor-1 production by very low-density lipoprotein involves transcription factor binding to a VLDL-responsive element [J]. Thromb Haemost,2000;84(4):706~711.
  • 7[7]Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients [J]. Lancet,1996;347:849~853.
  • 8[8]Mehrabian M, Peter JB, Barnard RJ, et al. Dietary regulation of fibri nolytic factors [J]. Atherosclerosis,1990;84:25.
  • 9[9]Primrose JN, Davies JA, Prentice CRM, et al. Reduction in factor Ⅲ, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity [J]. Thromb Haemostasis,1992;68:396.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部